MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide highlights from
Our October Newsletter Highlights: 🔹 Scientific poster accepted at AACR Ovarian Cancer Conference 🔹 Strategic partnership signed with Prestige Biopharma for pancreatic cancer 🔹 Imagion
Highlights: Reduces operating expenses Update on MagSense® HER2 program MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it
1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan
Dear Imagion Biosystems Shareholders, It has been an incredible first month ramping up as Chief Executive Officer with Team Imagion Biosystems. With this quarter’s 4C
Highlights include: MagSense® HER2 Phase 1 Study achieves enrolment target Expands collaboration with Siemens Healthineers Dr. Isaac Bright appointed as CEO MELBOURNE – Imagion Biosystems (ASX:IBX),
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has
Highlights Study achieves enrolment target Study to formally close to new enrolments on 31 July Study results support further clinical development as MRI imaging agent
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce it has appointed Isaac